Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...
Deals
Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development
Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...
BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish...
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires
Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer...
Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China,...
Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem
Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...
Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...
BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million
BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and...
Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912
Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a...
Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers
Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....
Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment
Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...